Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (β-D-mannuronic Acid) as a Novel NSAID with Immunosuppressive Property
| Autor: | Zohreh Babaloo, Mozhgan Jahanbakhshi, Hossein Ahmadi, Abbas Mirshafiey, Seyed Shahabeddin Mortazavi-Jahromi, Maryam Monsef Shokri |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug Adult Male medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism media_common.quotation_subject Arthritis Rheumatoid 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Dehydroepiandrosterone sulfate Internal medicine medicine Mannuronic acid Immunology and Allergy Humans Progesterone media_common medicine.diagnostic_test Estradiol business.industry Dehydroepiandrosterone Sulfate Hexuronic Acids Anti-Inflammatory Agents Non-Steroidal Middle Aged medicine.disease Up-Regulation Sexual hormones Clinical trial 030104 developmental biology Endocrinology Treatment Outcome chemistry 030220 oncology & carcinogenesis Rheumatoid arthritis Immunoassay Female business Immunosuppressive Agents Hormone |
| Zdroj: | Endocrine, metabolicimmune disorders drug targets. 18(5) |
| ISSN: | 2212-3873 |
| Popis: | BACKGROUND Based on in-vitro, in-vivo and human studies, the β-D-mannuronic acid (M2000) has been introduced as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties. OBJECTIVE This study aimed to evaluate the efficacy of this drug on serum level of sex hormones (Estradiol, Progesterone, and DHEAS) in rheumatoid arthritis (RA) patients. METHODS The present research was performed on 10 RA patients who had an inadequate response to conventional treatments (clinical trial identifier: IRCT2014011213739N2). During this trial, the patients were permitted to continue the conventional therapy along with adding M2000 orally at a dose of 500 mg twice daily for 12 weeks. Serum samples were collected in a normal group, patient group (at baseline) and treatment group (after 12 weeks). The samples were tested for evaluating the serum level of Estradiol, Progesterone, and DHEAS using chemiluminescent microparticle immunoassay. RESULTS Data showed that the serum level of estradiol was reduced (both in men and women) during the treatment with M2000 (after 12 weeks), but there was no significant difference in the non-treated group with M2000 (p > 0.05). In addition, the serum level of progesterone and DHEAS significantly increased following the 12-week administration of M2000 in both male and female patients, compared to the non-treated group with M2000 (p < 0.001, p < 0.05, p < 0.05, p < 0.01, respectively). CONCLUSION The present research showed that the sex hormones might be modified by M2000 therapy in RA patients by increasing the serum level of progesterone and DHEAS compared to healthy individuals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|